Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Part 6 — Psychological Drivers of Addiction: Stress, Emotion, and Trauma
Mohamad-Ali Salloum, PharmD • April 6, 2026
Share
How emotional dysregulation, traumatic experiences, and chronic stress shape vulnerability to addiction
Addiction is often described as a brain‑based disorder, but psychological factors—especially stress, trauma, and emotional regulation difficulties—play equally powerful roles in shaping who becomes addicted, how addiction progresses, and why relapse occurs. Recent findings highlight the profound interplay between early relational experiences, chronic emotional distress, and altered stress‑response systems. These factors do not simply influence addiction from the outside; they fundamentally reshape the brain’s motivational and emotional circuitry.
This section explores how psychological forces interact with biological systems to increase vulnerability to addictive behaviors.
1. Early Attachment and Trauma: Emotional Foundations of Vulnerability 🧩
Early relational trauma—such as inconsistent caregiving, emotional neglect, or chronic instability—can dysregulate the stress‑response system and impair the ability to regulate emotions later in life. These disruptions affect brain regions involved in self‑awareness, emotional processing, and reward, including the insula, which plays a major role in interpreting internal emotional states.
In simple terms:
Early emotional wounds weaken the brain’s ability to manage stress, making addictive coping more likely.
Early emotional wounds weaken the brain’s ability to manage stress, making addictive coping more likely.
2. Stress: A Core Driver of Addiction and Relapse ⚡
Stress is one of the most powerful psychological triggers for both substance use and relapse. Chronic or repeated stress disrupts the body’s adaptive stress mechanisms, making emotional and physiological recovery more difficult. When individuals face ongoing stress—such as trauma history, conflict, or unstable environments—the stress system becomes hypersensitive.
- increases craving
- reduces impulse control
- amplifies negative emotional states
- makes substance use feel like quick relief
- strengthens associations between stress and drug-seeking behavior
In simple terms:
When stress builds up faster than the brain can cope, addictive behaviors become an escape valve.
When stress builds up faster than the brain can cope, addictive behaviors become an escape valve.
3. Emotional Dysregulation: When Feelings Become Overwhelming 🌧️
Emotional dysregulation—difficulty understanding, tolerating, or managing emotions—is consistently linked to addiction. Treatments designed to improve emotional regulation have shown positive outcomes, reducing relapse by helping individuals build healthier tools for handling distress.
Different substances also affect emotional processing differently:
- Alcohol dependence: blunted response to negative emotional cues
- Cocaine dependence: heightened sensitivity to negative emotions
- Opioid dependence: strong links to amygdala dysfunction
In simple terms:
People don’t always use substances to feel good—they often use them to stop feeling bad.
People don’t always use substances to feel good—they often use them to stop feeling bad.
4. Trauma and PTSD: A Powerful Predictor of Substance Misuse 🔥
Trauma and substance use disorders frequently occur together. Individuals with PTSD face heightened emotional vulnerability and often struggle to regulate both negative and positive emotions. Substances may temporarily numb distress, but this relief reinforces dependence over time.
- trauma increases emotional vulnerability
- substances provide short-term escape
- emotional dysregulation intensifies
- avoidance becomes a learned strategy, deepening dependence
In simple terms:
Trauma disrupts emotional stability, and substances become a shortcut to escape overwhelming internal experiences.
Trauma disrupts emotional stability, and substances become a shortcut to escape overwhelming internal experiences.
5. How Psychological Factors Contribute to Relapse 🔄
Relapse is frequently triggered by psychological vulnerabilities—many rooted in earlier trauma, chronic stress, or emotional dysregulation.
Common psychological relapse triggers:
- negative mood or distress
- family conflict or high emotional tension
- cravings triggered by emotional cues
- peer pressure
- unresolved trauma symptoms
In simple terms:
Relapse happens when emotional discomfort collides with old learned coping habits.
Relapse happens when emotional discomfort collides with old learned coping habits.
6. An Integrated Picture: Emotions, Stress, and Trauma in Addiction 🧠
Across research, a unified picture emerges:
- early attachment disruptions create long-term vulnerability
- trauma destabilizes emotional and stress systems
- emotional dysregulation fuels cycles of negative reinforcement
- chronic stress reduces resilience and heightens cravings
- psychological suffering becomes interconnected with drug-seeking behavior
This explains why psychological treatment—including emotional regulation training, trauma processing, and stress resilience building—is essential in addiction recovery.
✅ Quick Quiz: Test Your Understanding
Try answering these before scrolling back!
- How do early attachment disruptions increase addiction risk?
- Why is stress considered one of the strongest triggers for relapse?
- Describe one way emotional dysregulation contributes to addictive behavior.
- How does PTSD increase vulnerability to substance use disorders?
- Give one example of a psychological relapse trigger and explain its power.
References:
- Unterrainer HF. Addiction, attachment, and the brain: a focused review of empirical findings. Front Hum Neurosci. 2025;19. 1
- Sinha R. Stress and substance use disorders: risk, relapse, and treatment outcomes. J Clin Invest. 2024;134(16). 2
- Chrétien S, Giroux I, Smith I, et al. Emotional Regulation in Substance-Related and Addictive Disorders Treatment: A Systematic Review. J Gambl Stud. 2025;41:353–448. 3
- Hand LJ, Paterson LM, Lingford-Hughes AR. Emotional dysregulation as a driver of relapse. Transl Psychiatry. 2024;14:467. 4
- Bowen AM, Calder R, Neale J, et al. Emotion Regulation in the Association Between PTSD and Substance Use: A Systematic Review. Trauma Violence Abuse. 2024;27(1):3–21. 5
- Abdelkader Husiny TM. A Scoping Review of Factors Contributing to Relapse in Substance Use Disorders. Modern Journal of Health and Applied Sciences. 2025;2(1). 6
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
Discover the best ways to learn new skills
Stuck in your head? Discover why overthinking feels productive, how it sabotages your performance, and simple ways to shift into real action.
References: Wood W, Quinn JM, Kashy DA. Habits in everyday life: Thought, emotion, and action. J Pers Soc Psychol . 2002;83(6):1281–1297. Wood W, Neal DT. The habitual consumer. J Consum Psychol . 2009;19(4):579–592. Neal DT, Wood W, Labrecque JS, Lally P. How do habits guide behavior? Perceived and actual triggers of habits in daily life. J Exp Soc Psychol . 2012;48(2):492–498. Wood W, Mazar A, Neal DT. Habits and goals in human behavior: Separate but interacting systems. Perspect Psychol Sci . 2021;16(1):1–16. Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci . 2008;31:359–387. Smith KS, Graybiel AM. Habit formation. Dialogues Clin Neurosci . 2016;18(1):33–43. Yin HH, Knowlton BJ. The role of the basal ganglia in habit formation. Nat Rev Neurosci . 2006;7(6):464–476. Graybiel AM. The basal ganglia and chunking of action repertoires. Neurobiol Learn Mem . 1998;70(1–2):119–136. Schultz W. Dopamine reward prediction error coding. Dialogues Clin Neurosci . 2016;18(1):23–32. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science . 1997;275(5306):1593–1599. Nasser HM, Calu DJ, Schoenbaum G, Sharpe MJ. The dopamine prediction error: Contributions to associative models of reward learning. Front Psychol . 2017;8:244. Kahnt T, Schoenbaum G. The curious case of dopaminergic prediction errors and learning associative information beyond value. Nat Rev Neurosci . 2025;26:169–178. Lally P, van Jaarsveld CHM, Potts HWW, Wardle J. How are habits formed: Modelling habit formation in the real world. Eur J Soc Psychol . 2010;40(6):998–1009. American Psychological Association. Harnessing the power of habits. Monitor Psychol . 2020;51(8):78–83.
References: Baddeley A. Working memory: theories, models, and controversies. Annu Rev Psychol . 2012;63:1–29. Chai WJ, Abd Hamid AI, Malin Abdullah J. Working memory from the psychological and neurosciences perspectives: a review. Front Psychol . 2018;9:401. Rogers RD, Monsell S. Costs of a predictable switch between simple cognitive tasks. J Exp Psychol Gen . 1995;124(2):207–231. Rubinstein JS, Meyer DE, Evans JE. Executive control of cognitive processes in task switching. J Exp Psychol Hum Percept Perform . 2001;27(4):763–797. Garner KG, Dux PE. Knowledge generalization and the costs of multitasking. Nat Rev Neurosci . 2023;24:98–112. Zhou X, Lei X. Wandering minds with wandering brain networks. Neurosci Bull . 2018;34(6):1017–1028. Sorella S, Crescentini C, Matiz A, et al. Resting‑state default mode network variability predicts spontaneous mind‑wandering. Front Hum Neurosci . 2025;19:1515902. Sweller J. Cognitive load during problem solving: effects on learning. Cogn Sci . 1988;12(2):257–285.
Why do we procrastinate even when tasks matter most? Discover the emotional roots of procrastination and how to stop
Confidence and self-esteem are often confused but are psychologically distinct. Learn how they differ, how each develops, and why understanding both matters for real growth.
Confidence isn’t about eliminating fear—it’s about acting despite it. Discover how courage, discomfort, and psychological growth build real confidence over time.
References: McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med . 2014;371(11):993–1004. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med . 2007;357:2109–2122. Kastelein JJP, Akdim F, Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med . 2008;358:1431–1443. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med . 2008;358:2545–2559. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med . 1991;324:781–788. Packer M, Anker SD, Butler J, et al. Effect of empagliflozin on cardiovascular and renal outcomes. N Engl J Med . 2020;383:1413–1424. Ioannidis JPA. Surrogate endpoints in clinical trials: are we being misled? BMJ . 2013;346:f314.
References: Wager TD, Atlas LY. The neuroscience of placebo effects: connecting context, learning and health. Nat Rev Neurosci . 2015;16(7):403‑18. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects associated with pharmacological interventions: an umbrella review. BMJ Open . 2023;13:e077243. Colloca L, Finniss D. Nocebo effects, patient‑clinician communication, and therapeutic outcomes. JAMA . 2012;307(6):567‑8. Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a blinded, randomized trial of statin, placebo, and no treatment. N Engl J Med . 2021;385(23):2180‑9. Penson PE, Mancini GBJ, Toth PP, et al. Introducing the “drucebo” effect in statin therapy. J Cachexia Sarcopenia Muscle . 2018;9(6):1023‑33. Barnes K, Faasse K, Geers AL, et al. Can positive framing reduce nocebo side effects? Front Pharmacol . 2019;10:167. Caliskan EB, Bingel U, Kunkel A. Translating knowledge on placebo and nocebo effects into clinical practice. Pain Rep . 2024;9(2):e1142. von Wernsdorff M, Loef M, Tuschen‑Caffier B, Schmidt S. Effects of open‑label placebos in clinical trials: a systematic review and meta‑analysis. Sci Rep . 2021;11:3855.
References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to distinguish correlation from causation in orthopaedic research. J Arthroplasty. 2023;38(4):634–637. Rush J, Ajami M, Look KA, Margolis A. Statistics review part 10: causality and confounding. J Pharm Soc Wis. 2014;17(1):45–52. Koopmans E, Schiller C. Understanding causation in healthcare: an introduction to critical realism. Qual Health Res. 2022;32(8–9):1207–1214. Kahlert J, Gribsholt SB, Gammelager H, Dekkers OM, Luta G. Control of confounding in the analysis phase – an overview for clinicians. Clin Epidemiol. 2017;9:195–204. Shi AX, Zivich PN, Chu H. A comprehensive review and tutorial on confounding adjustment methods for estimating treatment effects using observational data. Appl Sci (Basel). 2024;14(9):3662. Gao Y, Xiang L, Yi H, Song J, Sun D, Xu B, et al. Confounder adjustment in observational studies investigating multiple risk factors: a methodological study. BMC Med. 2025;23:132. Ho FK, Brown J, Galwey NW. Regression adjustment for causal inference. BMJ Med. 2025;4:e000816. Correia LCL, Mascarenhas RF, Menezes FSC, Oliveira Junior JS, Vaccarino V, Ross JS, et al. Confounder selection in observational studies in high‑impact medical and epidemiological journals. JAMA Netw Open. 2025;8(7):e2524176.